Effect of tamoxifen treatment on cortisol metabolism and the course of the disease in advanced breast cancer

Levin, Joseph; Markham, Mark J.; Greenwald, Edward S.; Wollner, David; Kream, Jacob; Zumoff, Barnett; Fukushima, David K.

doi:10.1002/1097-0142(19810315)47:6<1394::aid-cncr2820470625>3.0.co;2-6

Cited by 10 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, tamoxifen has been shown to substantially increase plasma cortisol concentrations in patients with breast cancer. 33 Cortisol is a powerful lipolytic hormone and is connected to increased fat metabolism at rest and during exercise. 34 The resulting lipolysis from cortisol elevation can be further enhanced through estrogen (or tamoxifen acting like estrogen), by its action of promoting growth hormone (hGH) release from the anterior pituitary.…”

Section: Discussionmentioning

confidence: 99%

Exercise in Patients With Breast Cancer and Healthy Controls: Energy Substrate Oxidation and Blood Lactate Responses

et al. 2010

View full text Add to dashboard Cite

The aim of this study was to compare select aspects of exercise energy metabolism in patients with breast cancer with that of healthy controls across a variety of exercise intensities. Posttreated patients with breast cancer were matched with healthy women based on age, physical fitness level, and menopausal status. Subjects participated in low-, moderate-, and high-intensity submaximal exercise sessions that corresponded with 40% of maximal oxygen consumption (Vo 2max ), 60% Vo 2max , and 70% Vo 2max . Oxygen consumption and respiratory exchange ratio were taken during submaximal exercise sessions to determine substrate oxidation rates for carbohydrate (CHO) and fat. Blood lactate and blood glucose were also measured before and after each of the submaximal exercise sessions as indices of CHO metabolism. Results indicate that the patients with breast cancer had a significantly (P ≤ .05) lower CHO oxidation rate and higher fat oxidation rate at all exercise intensities compared with healthy women. The patients with breast cancer had a significantly (P ≤ .05) lower blood lactate response to exercise across all intensities compared with the healthy women. Glucose responses tended (P < .08) to be more elevated in patients with cancer both before and after the exercise sessions. The findings indicate that posttreated patients with breast cancer have augmented fat metabolism and a reduced CHO-based energy metabolism during submaximal exercise. It is unclear whether these changes are the result of the patient's cancer or their treatment regimen for the cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Exercise in Patients With Breast Cancer and Healthy Controls: Energy Substrate Oxidation and Blood Lactate Responses

et al. 2010

View full text Add to dashboard Cite

show abstract

Medroxyprogesterone acetate lowers plasma corticotropin and cortisol but does not suppress anterior pituitary responsiveness to human corticotropin releasing factor

Lang

Zielinski

Templ

et al. 1990

Cancer

View full text Add to dashboard Cite

The endocrine action of medroxyprogesterone acetate (MPA) has been claimed to be of a glucocorticoid‐like nature. Upon clinical observation, MPA has been shown to improve life quality and overall well‐being in patients with advanced breast cancer, renal carcinoma, prostatic carcinoma, and uterine adenocarcinoma. The authors have evaluated MPA endocrine action by the administration of human corticotropin releasing factor (hCRF) in a 90‐minute assay in 15 patients with advanced breast cancer or renal cell carcinoma both, before the initiation of oral high‐dose MPA treatment (1000 mg MPA) as well as after at least 10 days of therapy. The curves for corticotropin, β‐endorphin, and cortisol responses to hCRF of tumor patients who were tested before the initiation of MPA treatment were parallel to the curves of a healthy control group of probands tested under equal conditions, although at significantly higher respective hormone levels. In patients with malignant disorders assayed after MPA administration, both basal and peak hormone levels were found to be comparable with values obtained in healthy controls. In conclusion, MPA appeared to act at a suprapituitary level since pituitary responsiveness to hCRF was preserved under MPA treatment. Moreover, it appeared that MPA brought the hormonal stress state found in patients with malignant tumors back to normal.

show abstract

The pharmacology and clinical uses of tamoxifen

Furr¹,

Jordan

1984

Pharmacology & Therapeutics

845

365

View full text Add to dashboard Cite

Effect of tamoxifen treatment on cortisol metabolism and the course of the disease in advanced breast cancer

Cited by 10 publications

References 9 publications

Exercise in Patients With Breast Cancer and Healthy Controls: Energy Substrate Oxidation and Blood Lactate Responses

Exercise in Patients With Breast Cancer and Healthy Controls: Energy Substrate Oxidation and Blood Lactate Responses

Medroxyprogesterone acetate lowers plasma corticotropin and cortisol but does not suppress anterior pituitary responsiveness to human corticotropin releasing factor

The pharmacology and clinical uses of tamoxifen

Contact Info

Product

Resources

About